Pfizer, Inc. announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the 100 mg and 200 mg doses of abrocitinib, an oral, once-daily, Janus kinase 1 inhibitor, for marketing authorization to treat moderate to severe atopic dermatitis in adults who are candidates for systemic therapy.
[Pfizer, Inc.]
6445218
{6445218:AAAAAAAA}
apa
50
1
167895
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/